FIELD: pharmaceuticals.
SUBSTANCE: present invention relates to the pharmaceutical industry, namely, to a replication inhibitor of the SARS-CoV-2 coronavirus that causes severe acute respiratory syndrome COVID-19. The natural melanin from the basidiomycetes Inonotus obliquus is used, obtained by alkaline hydrolysis of Inonotus obliquus, acid precipitation, dissolution of the precipitate in ammonia water and drying of the final product at a temperature not exceeding 30-40ºC, as a replication inhibitor of SARS coronavirus. An aqueous solution of this inhibitor in the range of 6,218-8,488 mcg/ml exhibits 50% antiviral dose-dependent activity against SARS-CoV-2 in tests on Vero cell culture.
EFFECT: above-described natural melanin exhibits 50% antiviral dose-dependent activity against SARS-CoV-2 in Vero cell culture tests.
1 cl, 1 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SARS-COV-2 REPLICATION INHIBITOR BASED ON A WATER EXTRACT OF THE FUNGUS INONOTUS OBLIQUUS | 2020 |
|
RU2741714C1 |
| SARS-CoV-2 CORONAVIRUS REPLICATION INHIBITOR BASED ON HUMIC SUBSTANCES | 2020 |
|
RU2752872C1 |
| METHOD FOR OBTAINING AN AQUEOUS EXTRACT OF FIREWEED LEAVES EPILOBIUM ANGUSTIFOLIUM L., WHICH EXHIBITS INHIBITORY ACTIVITY AGAINST SARS-CoV-2 CORONAVIRUS AND HERPES SIMPLEX VIRUS TYPE 2 IN VITRO | 2022 |
|
RU2788172C1 |
| MELANINE ANTIVIRAL AGENT | 2011 |
|
RU2480227C2 |
| WOUND HEALING OINTMENT FOR EXTERNAL USE | 2022 |
|
RU2787233C1 |
| WATER-SOLUBLE PIGMENT MELANIN FROM THE BASIDIOMYCETE INONOTUS OBLIQUUS WITH ANTIVIRAL ACTIVITY | 2022 |
|
RU2800446C1 |
| AN ANTIVIRAL AGENT AGAINST SARS-COV-2 CORONAVIRUS | 2022 |
|
RU2788762C1 |
| STRAIN OF BASIDIOMYCETE INONOTUS OBLIQUUS - PRODUCER OF MELANIN PIGMENT POSSESSING ANTIVIRAL AND ANTITUMORAL ACTIVITY | 2019 |
|
RU2716590C1 |
| INHIBITOR OF REPRODUCTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 | 2008 |
|
RU2375073C1 |
| NUTRIENT MEDIUM FOR CULTIVATING BASIDIOMYCETE FUNGUS INONOTUS OBLIQUUS | 2021 |
|
RU2808749C2 |
